Loading
Medicinova Inc Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Matsuda Kazuko, was filed 13 Mar 2020.
Medicinova Inc: what insiders have been doing
Medicinova Inc, classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Between 24 October 2025 and 24 October 2026, 1 insider published 1 filing.
No insider bought on the market over the period, while 1 insider filed 1 sale totalling €1.5M. The largest single trade was a sale of €1.5M by 3D Investment Partners Pte. Ltd., published on 29 September 2026, equal to 2.6% of the market capitalisation.
Compared with its exchange (3,167 companies, median 24 filings), a count of 1 filing is below the norm. Since 2006, the database holds 42 purchases and 11 sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 409,657 USD and net income of -12.0 m USD.
Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
97
Thresholds
n/a
Buy Volume
€1M
42 ops. · all time
Sell Volume
€2M
11 ops. · all time
Who traded when
BuySale3D Investment Partners Pte. Ltd.1 sale
Since the insiders bought
- +65.9%Entry US$3.93 · Close at T+365 US$6.52
- +61.8%Entry US$4.03 · Close at T+365 US$6.52
- +101.5%Entry US$5.23 · Close at T+365 US$10.54
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 25,649 of 26,290 companies
10.8
score / 100
Value12
Quality9
FCF yld-14%
Earn yld-18%
EV/EBITDA·
ROE-26%
Gross mgn7.6%
Net mgn·
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$1.39
Analyst consensus
4 analysts1.25/5
US$6.00Target US$8.25(+494%)US$11.00
Income statement
RevenueUS$409.7k
Gross profitUS$31.1k8% margin
EBITDA-US$13.3M-3238% margin
Net income-US$12M-2928.8% margin
Valuation
PER (forward)-2.7x
P/Book1.8x
Beta0.61
Balance sheet & cash
Market capUS$68.4M
Total debtUS$194.3k
Free Cash Flow-US$9.8M
Debt / Equity0%
Profitability & ownership
ROE-25.6%
ROA-16.4%
% insiders2.9%
% institutions20.4%
Last declaration on 29 September 2026
Declarations97 total
640,000 shares@ US$2.702.61% mcap100.0% of flowCommon StockSEC:0001213900-26-104739:0
6,754 shares@ US$2.2555.0% of flowCommon StockSEC:0001683168-22-008111:0
218 shares@ US$2.130.6% of flowCommon StockSEC:0001683168-22-008020:1
5,365 shares@ US$2.1842.5% of flowCommon StockSEC:0001683168-22-008020:0
309 shares@ US$2.182.4% of flowCommon StockSEC:0001683168-22-007952:0
60,000 shares@ US$2.3054.2% of flowCommon StockSEC:0001683168-21-003893:0
39,583 shares@ US$2.54100.0% of flowCommon StockSEC:0001683168-21-003082:0
56,250 shares@ US$2.4617.7% of flowCommon StockSEC:0001683168-21-002744:1
46,554 shares@ US$2.5445.8% of flowCommon StockSEC:0001683168-21-002744:0
11,318 shares@ US$2.4617.9% of flowCommon StockSEC:0001683168-21-002130:1
32,000 shares@ US$2.54100.0% of flowCommon StockSEC:0001683168-21-002130:0
2,354 shares@ US$7.4018.0% of flowCommon StockSEC:0001683168-21-000953:0
86,250 shares@ US$2.4620.4% of flowCommon StockSEC:0001683168-21-000740:0
1,000 shares@ US$5.787.6% of flowCommon StockSEC:0001683168-20-003158:0
15,000 shares@ US$2.5850.8% of flowCommon StockSEC:0001683168-20-002584:0
20,000 shares@ US$5.1323.5% of flowCommon StockSEC:0001683168-20-001952:0
28,446 shares@ US$2.5417.2% of flowCommon StockSEC:0001683168-20-001158:0
60,417 shares@ US$2.5450.2% of flowCommon StockSEC:0001683168-20-001157:0
2,000 shares@ US$3.621.7% of flowCommon StockSEC:0001683168-20-000807:0
Canonical exit: 11 Jun 2020 (T+90)
20,000 shares@ US$3.1019.6% of flowCommon StockSEC:0001683168-20-000786:0
Canonical exit: 10 Jun 2020 (T+90)
37,000 shares@ US$4.8029.2% of flowCommon StockSEC:0001683168-19-001890:0
1,000 shares@ US$2.773.7% of flowCommon StockSEC:0001683168-19-001515:0
35,700 shares@ US$7.346.9% of flowCommon StockSEC:0001683168-19-000530:0
85,000 shares@ US$2.545.7% of flowCommon StockSEC:0001683168-19-000530:1
63,750 shares@ US$2.464.1% of flowCommon StockSEC:0001683168-19-000530:2
25 of 97 declarations
About Medicinova Inc
MediciNova, Inc. (ticker: MNOV) is a U.S.-listed biopharmaceutical company traded on the NASDAQ market in the United States, with an additional listing relationship in Tokyo. From an international equity perspective, MNOV is best understood as a clinical-stage small-cap biotech rather than a commercial pharma platform. The company was founded in September 2000 in San Diego, California, and its operational base is in La Jolla, within the San Diego biotech corridor. Its founding strategy was to acquire and accelerate the global development and commercialization of innovative pharmaceutical products through alliances with biotechnology and pharmaceutical partners in North America, Europe, and Japan. ([medicinova.com](https://medicinova.com/company/medicinova-history/))
MediciNova’s business is centered on a clinical pipeline rather than a mature product portfolio. The company describes itself as a clinical-stage biopharmaceutical developer of novel small-molecule therapies targeting inflammatory, fibrotic, and neurodegenerative diseases. Its development strategy is organized around two core compounds, MN-166 (ibudilast) and MN-001 (tipelukast), each being evaluated across multiple indications. In its recent shareholder communication, the company stated that it has 11 programs in clinical development, underscoring a multi-asset, multi-indication pipeline strategy aimed at value creation through proof-of-concept and late-stage clinical milestones. ([investors.medicinova.com](https://investors.medicinova.com/news-releases/news-release-details/medicinova-provides-shareholder-update-key-developments/))
Read moreShow less
Historically, the company has built its pipeline largely through in-licensing from Japanese and European partners, which allowed MediciNova to assemble a portfolio without relying solely on internal discovery. This approach has shaped the company into a development-focused biotech with international roots and a relatively capital-efficient origin story. MediciNova became publicly traded on the NASDAQ Global Market in December 2006 under the MNOV symbol, giving it access to the U.S. public equity market while remaining a global collaboration-driven developer. ([medicinova.com](https://medicinova.com/company/medicinova-history/))
In competitive terms, MediciNova operates in a highly differentiated niche of the biotech sector: programs address serious diseases with significant unmet medical need, but the company competes indirectly with larger pharmaceutical groups, specialist biotechs, and emerging gene- and cell-therapy approaches. Its value proposition depends on clinical data quality, regulatory progress, strategic partnerships, and access to capital. The company’s geographic footprint remains anchored in the United States, but its origins and partnering model are clearly international, especially in Japan, where some of the licensed programs originated. ([medicinova.com](https://medicinova.com/company/medicinova-history/))
Recent developments have been important for the investment case. In 2025, MediciNova highlighted progress in its COMBAT-ALS Phase 2b/3 trial of MN-166 for amyotrophic lateral sclerosis and noted a large Expanded Access Program supported by a $22 million NIH grant. The company also disclosed a standby equity purchase agreement that could provide up to $30 million of capital over 36 months. For investors, that combination is typical of development-stage biotech: encouraging clinical momentum, but continuing financing needs and meaningful dilution risk. As a result, MNOV should be viewed as a catalyst-driven NASDAQ biotech name in the United States, where future valuation is highly dependent on trial execution and regulatory optionality. ([investors.medicinova.com](https://investors.medicinova.com/news-releases/news-release-details/medicinova-provides-shareholder-update-key-developments/))
